Deutsche Bank AG Buys 652,923 Shares of Edwards Lifesciences Co. (NYSE:EW)

Deutsche Bank AG raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 10.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,903,202 shares of the medical research company's stock after purchasing an additional 652,923 shares during the quarter. Deutsche Bank AG owned approximately 1.17% of Edwards Lifesciences worth $511,044,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of EW. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $26,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $30,000. Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $54,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on EW shares. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Royal Bank of Canada reissued an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. StockNews.com raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Thursday. Finally, Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $79.45.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 89,681 shares of company stock worth $6,492,703 in the last three months. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.81 during trading on Friday, reaching $73.82. The company had a trading volume of 3,814,732 shares, compared to its average volume of 5,043,358. The firm's 50-day simple moving average is $71.48 and its 200 day simple moving average is $71.50. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $43.40 billion, a price-to-earnings ratio of 10.59, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.66 EPS. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.